Cargando…
Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
Ewing's sarcoma (ES) associated with high osyeolytic lesions typically arises in the bones of children and adolescents. The development of multi-disciplinary therapy has increased current long-term survival rates to greater than 50% but only 20% for high risk group patients (relapse, metastases...
Autores principales: | Picarda, Gaëlle, Matous, Etienne, Amiaud, Jérôme, Charrier, Céline, Lamoureux, François, Heymann, Marie-Françoise, Tirode, Franck, Pitard, Bruno, Trichet, Valérie, Heymann, Dominique, Redini, Françoise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723385/ https://www.ncbi.nlm.nih.gov/pubmed/26909278 http://dx.doi.org/10.1016/j.jbo.2013.04.004 |
Ejemplares similares
-
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration
por: Odri, Guillaume, et al.
Publicado: (2014) -
Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1
por: Jacques, Camille, et al.
Publicado: (2016) -
Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
por: Redini, Françoise, et al.
Publicado: (2015) -
Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases
por: Lamora, Audrey, et al.
Publicado: (2015) -
Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma
por: Muñoz-Garcia, Javier, et al.
Publicado: (2022)